The effects of a PCSK9-inhibitor on various lipid fractions
Gisette Reyes-Soffer (Columbia University Medical Center, New York City, NY, USA)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs Gisette Reyes-Soffer shares the findings on the effect of PCSK9-inhibitor alirocumab on VLDL, IDL, LDL and apoB-metabolism in healthy volunteers.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.